FRLN Stock Overview
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Freeline Therapeutics Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.48 |
| 52 Week High | US$8.70 |
| 52 Week Low | US$2.11 |
| Beta | 0.66 |
| 1 Month Change | 1.25% |
| 3 Month Change | 1.73% |
| 1 Year Change | -21.67% |
| 3 Year Change | -97.13% |
| 5 Year Change | n/a |
| Change since IPO | -97.60% |
Recent News & Updates
Recent updates
Calculating The Intrinsic Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)
Jul 13
Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely
Apr 11Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely
Dec 20We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate
Aug 30Freeline gains as NEJM publishes long-term data for hemophilia therapy
Jul 21Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?
May 05Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?
Jan 13Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky
Sep 30Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation
Jun 03What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?
Feb 18
Shareholder Returns
| FRLN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.2% | -0.4% | -0.6% |
| 1Y | -21.7% | 5.4% | 22.5% |
Return vs Industry: FRLN underperformed the US Biotechs industry which returned 4.4% over the past year.
Return vs Market: FRLN underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| FRLN volatility | |
|---|---|
| FRLN Average Weekly Movement | 3.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: FRLN's share price has been volatile over the past 3 months.
Volatility Over Time: FRLN's weekly volatility has decreased from 17% to 4% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 152 | Michael Parini | www.freeline.life |
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy.
Freeline Therapeutics Holdings plc Fundamentals Summary
| FRLN fundamental statistics | |
|---|---|
| Market cap | US$28.25m |
| Earnings (TTM) | -US$49.93m |
| Revenue (TTM) | US$622.00k |
45.4x
P/S Ratio-0.6x
P/E RatioIs FRLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FRLN income statement (TTM) | |
|---|---|
| Revenue | US$622.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$622.00k |
| Other Expenses | US$50.55m |
| Earnings | -US$49.93m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.45 |
| Gross Margin | 100.00% |
| Net Profit Margin | -8,027.65% |
| Debt/Equity Ratio | 0% |
How did FRLN perform over the long term?
See historical performance and comparison